US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

Arogya Aarohan app & other AI-driven tools are being tested for early detection of diseases as part of Rs 300-cr initiative ...

Health scientists from the University of Virginia have found a previously unknown contributor to harmful blood vessel growth ...

About AXPAXLI AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI) is an investigational, bioresorbable, hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase ...

The FDA previously agreed that together, these studies could constitute two adequate and well-controlled trials to support a potential New Drug Application ... injections due to the high treatment ...

AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program.